Mr. Ronan will lead a discussion that explores the Trump Administration's attempt to balance a healthcare agenda aimed at de-regulation and reducing the time and cost to develop medicines with other initiatives, such as most favored nation pricing, tariffs, tax and regulatory incentives to increase domestic manufacturing capabilities, expeditated review of therapies that align with national health priorities, and the reduction of staff and budget at key agencies such as the Food and Drug Administration (FDA) and the National Institutes of Health (NIH).
Key Learning Objectives
- Analyze the Trump Administration's approach to deregulating healthcare and its impact on drug development timelines and costs.
- Evaluate the implications of policy initiatives such as most favored nation pricing, tariffs, tax and regulatory incentives to increase domestic manufacturing capabilities.
- Assess the effect of staffing and budget reductions at key health agencies like the FDA and NIH.
